Blog

  • NanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer

    NanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer

    MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...

    Read
  • 9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

    Read
  • 8 Gene Therapy conferences you should attend in 2022

    8 Gene Therapy conferences you should attend in 2022

    With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...

    Read
  • NanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine optimal protein labeling strategy

    NanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine optimal protein labeling strategy

    MUNICH/DRESDEN, April 6, 2022—NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help...

    Read
  • 10 terms to help you more easily understand targeted protein degradation

    10 terms to help you more easily understand targeted protein degradation

    Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...

    Read
  • ×

    Sign up to receive
    the latest NanoTemper news, product updates, event announcements and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....

    Read
  • NanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs

    NanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs

    SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...

    Read
  • How do you get reproducible data from protein characterization experiments? Try following this DIN SPEC

    How do you get reproducible data from protein characterization experiments? Try following this DIN SPEC

    Reproducibility is a key tenet of scientific research, but many pharma groups have projects that collaborate across different sites or that rely on materials prepared by other specialist...

    Read
  • For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome

    For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome

    Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...

    Read
  • Have a question?

    Contact Specialist
  • Why so many companies are betting on PROTACs as a superior therapeutic modality

    Why so many companies are betting on PROTACs as a superior therapeutic modality

    With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

    Read
  • 5 formulation changes you can evaluate with Dynamic Light Scattering to increase your biologics candidates’ success

    5 formulation changes you can evaluate with Dynamic Light Scattering to increase your biologics candidates’ success

    Biologics researchers are deeply concerned with formulation. Formulation typically refers to the final development of a deliverable, biologically derived molecule (such as a protein, peptide,...

    Read
  • NanoTemper gets Top 100 award as one of Germany’s most innovative SMEs in 2021

    NanoTemper gets Top 100 award as one of Germany’s most innovative SMEs in 2021

    NanoTemper has been given this year’s TOP 100 seal, an award that honors innovative German small and medium-sized companies. The TOP 100 innovation competition is organized by compamedia, and...

    Read
  • NanoTemper’s Monolith wins top global design award: Red Dot Award

    NanoTemper’s Monolith wins top global design award: Red Dot Award

    NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal of excellence in design. Both bold aesthetics and user-friendly design have always...

    Read
  • NanoTemper launches Andromeda, helping Biopharma and CROs to increase efficiency of expression screening for membrane proteins

    NanoTemper launches Andromeda, helping Biopharma and CROs to increase efficiency of expression screening for membrane proteins

    SOUTH SAN FRANCISCO, Calif. June 24, 2021 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, enters the protein production market with...

    Read
  • 5 experiments in biologics that can be improved with dynamic light scattering

    5 experiments in biologics that can be improved with dynamic light scattering

    Biologics, which are drugs and treatments derived from natural products, undergo a long development process before they reach the clinic. When you invest a lot of time and money in the process to...

    Read
  • NanoTemper and SIRION Biotech support Adrian Bleninger’s bid for round-the-world sailing race, the Vendée Globe

    NanoTemper and SIRION Biotech support Adrian Bleninger’s bid for round-the-world sailing race, the Vendée Globe

    NanoTemper Technologies and SIRION Biotech, two of Munich’s rapidly growing biotech companies, are lending their support to Adrian Bleninger, a 30-year-old Bavarian sailor, in his bid to qualify...

    Read
  • NanoTemper named one of Germany’s most innovative companies in 2021 by Capital

    NanoTemper named one of Germany’s most innovative companies in 2021 by Capital

    For the second year in a row, NanoTemper was named one of the most innovative companies in Germany by Capital magazine. A five out of five star distinction placed NanoTemper in the ranking’s top...

    Read
  • Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

    Read
  • NanoTemper’s Monolith wins top global design award: iF DESIGN AWARD 2021

    NanoTemper’s Monolith wins top global design award: iF DESIGN AWARD 2021

    NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly design has always been a core focus in NanoTemper’s product development....

    Read
  • Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...

    Read
  • loading
    Loading more...